ABSI Stock Overview
Operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Absci Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.01 |
| 52 Week High | US$6.72 |
| 52 Week Low | US$2.45 |
| Beta | 2.03 |
| 1 Month Change | 17.58% |
| 3 Month Change | -22.42% |
| 1 Year Change | -24.75% |
| 3 Year Change | -62.84% |
| 5 Year Change | n/a |
| Change since IPO | -86.06% |
Recent News & Updates
Absci Corporation: Struggling To Live Up To Its AI Promise
Nov 20Is Absci (NASDAQ:ABSI) A Risky Investment?
Nov 13
Absci: Embryonic Pipeline Looks Expensive Relative To Peers
Oct 29Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Oct 03Recent updates
Absci Corporation: Struggling To Live Up To Its AI Promise
Nov 20Is Absci (NASDAQ:ABSI) A Risky Investment?
Nov 13Absci: Embryonic Pipeline Looks Expensive Relative To Peers
Oct 29Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Oct 03Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
Jul 28Is Absci (NASDAQ:ABSI) A Risky Investment?
Jun 17Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula
May 16Absci: Differentiated Antibody Discovery Play
Feb 27Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M
Aug 11Absci teams up to help develop antibody drugs for cancer
Jul 07Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out
Jan 10IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)
Jul 22Shareholder Returns
| ABSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.6% | -3.3% | -2.2% |
| 1Y | -24.8% | -1.9% | 23.9% |
Return vs Industry: ABSI underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: ABSI underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| ABSI volatility | |
|---|---|
| ABSI Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABSI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ABSI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 155 | Sean McClain | www.absci.com |
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Absci Corporation Fundamentals Summary
| ABSI fundamental statistics | |
|---|---|
| Market cap | US$345.72m |
| Earnings (TTM) | -US$97.67m |
| Revenue (TTM) | US$4.21m |
82.2x
P/S Ratio-3.5x
P/E RatioIs ABSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABSI income statement (TTM) | |
|---|---|
| Revenue | US$4.21m |
| Cost of Revenue | US$49.73m |
| Gross Profit | -US$45.52m |
| Other Expenses | US$52.15m |
| Earnings | -US$97.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | -1,082.08% |
| Net Profit Margin | -2,321.56% |
| Debt/Equity Ratio | 2.7% |
How did ABSI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 22:06 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Absci Corporation is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Tiago Fauth | Credit Suisse |
| Vamil Divan | Guggenheim Securities, LLC |